Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: John Curtis who wrote (779)	5/17/1999 10:37:00 AM
From: William Whitehead Jr.	Read Replies (1) \| Respond to of 2344

I was afraid of this. From talking to a number of people over the last couple of weeks I realized that they were expecting some early proof of the success of Phase III from ASCO. The bridging study was not properly understood. Can anyone confirm that one U.S. analyst (at M. Lynch?) has set a new target of $20 for the stock. Saw this posted Stockhouse yesterday. Whitey,

To: John Curtis who wrote (779)	5/17/1999 10:43:00 AM
From: Jibacoa	Respond to of 2344

<<<Some volatility today>>> Yes indeed.!!! The general market is not helping and a lot of people are "selling on the news" after the presentations of papers at ASCO on 5/15. Keep buying it on any dips. The long term outlook remains bright. Bernard

To: John Curtis who wrote (779)	5/17/1999 10:57:00 AM
From: Jibacoa	Respond to of 2344

Another thing that is not helping Biotecs in general is the big drop in IMNR today after the news that there was no apparent clinical improvement on the control vs. the treated group with REMUNE in spite of a drop on HIV virus counts. The stock had gone up recently on anticipation of REMUNE's FDA approval and the fact that Robert Gallo had joined the board. I think this news also affect BIOM indirectly Well if we still could get that "anticipated newspaper article" soon. Keep buying it on any dips. The ultimate outlook remains bright. Bernard